placeholder
Importance
55
Trust
70
Urgency
30
REGULATORY · PRIMARY SOURCE
HydraMed IV LLC dba HydraMed - 728282 - 06/08/2026
The FDA warned HydraMed, a Colorado pharmacy, for making false claims about its compounded semaglutide and tirzepatide products. The company falsely labeled itself as the maker of these drugs and claimed to be an FDA-approved pharmacy, which doesn't exist.
Analysis
FDA keeps cracking down on compounders selling fake-labeled semaglutide and tirzepatide. This pushes patients toward Novo and Lilly brand-name drugs.
- FDA issued warning letter to HydraMed IV LLC, Denver CO, dated June 8, 2026
- HydraMed falsely labeled itself as maker of compounded semaglutide and tirzepatide products
- HydraMed falsely claimed products came from an 'FDA-approved pharmacy,' a designation that does not exist
FDA Drug Approvals & Databases4d
Read